Fiinu Plc (AIM: BANK) — Investment Research Note
Executive summary
Fiinu is a sub-scale UK AIM fintech whose stated flagship is the "Plugin Overdraft®" — a bank-agnostic Open Banking overdraft platform intended to be white-labelled to lenders — which since 2023 has been paired with a recently acquired Polish FX brokerage (Everfex). Over the five-year window, the trajectory is one of repeated strategic reversals: reverse takeover of a cash shell (2022) → grant then return of a restricted UK banking licence (2022–2023) → drastic cost cut → first white-label heads of terms with Conister Bank (Jan 2025) → reverse takeover of Everfex (Aug 2025) → full £7.3m goodwill impairment of Everfex plus arbitration proceedings against the seller (2026). The single most important valuation point today is that at 4.0p / £15.8m market cap the shares imply meaningful optionality on both a successful Conister launch and Everfex's legal recovery, against tangible net assets of only £2.9m and a business still burning ~£220k/month.
Fair value estimate
- Range: 2p – 6p per share — implied market cap ~£8m – £24m (using 396m shares).
- Methodology: Sum-of-parts on a going-concern basis, since neither IFRS book value nor multiples of forward earnings are defensible.
- Net cash: £3.94m cash − £2.00m borrowings ≈ £1.9m 2026-06 FY25.
- Everfex FX business: carrying value fully impaired; unaudited profit before tax of PLN 3.15m (~£0.6m) over 4 months to Apr 2025 pre-Fiinu control but remediation, staff exits and non-compete arbitration have since disrupted the business. Value range £0m–£3m given ongoing legal/regulatory questions 2025-08 admission update; 2026-07 shareholder-letter response.
- Legal recoveries: management cites >£16m combined claim value, but recovery timing and probability are unquantifiable; risk-weighted low, £0m–£2m 2026-07 shareholder-letter response.
- Plugin Overdraft optionality: a single white-label with Conister targeting 1.4m Payment Assist customers, plus "10+ European banks in early discussions." No signed royalty rates disclosed. Weighted expected value £4m–£15m — very wide because a single deployment does not prove pricing power 2026-06 FY25.
- Less PV of central costs at current burn (~£2.5m/yr for ~2 years): −£2m to −£3m.
- Compared to £15.8m current mcap, our mid-point (~£13m /
3.3p) sits –18% vs. current 4.0p. The upper end of the range is **+50%**; the lower end is –50%. - View: fair to modestly overvalued on the central case, with a wide bull tail if Conister converts to real recurring revenue.
Sector context
- Sector classification (ICB Financials / Financial Services) is confirmed, but functionally the group is a fintech / vertical SaaS platform with a small FX brokerage appendage — not a bank (the banking licence was returned in 2023).
- Quality / growth / leverage profile is materially below typical listed UK fintech and specialty-finance peers: no meaningful recurring revenue, negative operating cash flow, heavy dilution history, going-concern language in FY24 audit.
- Comparable listed names (imperfect): Manx Financial Group (MFX.L) — Fiinu's own partner and a small UK specialty lender; Equals Group / Argentex (AGFX.L) — SME FX peers; Mode Global (MODE) (delisted) and other AIM Open-Banking micro-caps as cautionary comparators.
Investment thesis (three concrete reasons to own at 4p)
- Cheap optionality on the Conister white-label launch expected late summer 2026, targeting 1.4m existing Payment Assist customers — the first live commercial proof of the Plugin Overdraft technology and a template that management claims 10+ European banks are exploring 2026-06 FY25 final results.
- Net cash cushion and ~18 months of runway (£3.9m cash at Dec 2025 vs. average operational burn of ~£220k/month excluding exceptionals) reduces immediate wipe-out risk, and there is a live FX revenue line (£0.66m in FY25) that did not exist a year ago 2026-06 FY25 CEO statement.
- Contingent legal recovery upside: combined arbitration/warranty claims against the Everfex sellers exceed £16m — larger than the £7.3m goodwill impairment and more than 100% of current mcap; even a partial award would be materially value-accretive 2026-07 response to shareholder letter.
Key risks (three concrete reasons it could disappoint)
- Repeated strategic failure at group level: returned banking licence in 2023 after failing to raise exit capital, aborted Sprift transaction pre-RTO, fully impaired Everfex goodwill within 12 months, CFO/COO/CSO departures across 2024–2026 — the pattern is one of over-promised, under-delivered milestones 2023-09 operational update; 2026-06 FY25; 2026-06 board change.
- Dilution and financing risk: share count has grown from ~275m (Dec 2024) to 396m (2026) via multiple raises at 10p, then 15p, alongside £2m of borrowings; further capital will be required to obtain a UK banking licence (previously guided at £35–42m), and each raise at current 4p prices would be highly dilutive 2026-06 FY25 changes in equity; 2025-08 admission document.
- Governance and integration failures at Everfex: the acquired Polish FX business is subject to active arbitration against its former CEO for alleged non-compete breaches and against the seller for alleged warranty breaches, with the seller publicly circulating an activist letter to shareholders ahead of the July 2026 AGM — indicative of a distressed integration and continuing distraction 2026-07 response to shareholder letter.
Operating leverage
On paper the Plugin Overdraft is a classic high-leverage SaaS/platform — a fixed R&D and infrastructure base that would earn near-100% incremental margin on each additional bank deployment; the FY25 admin cost base of ~£2.4m is broadly fixed and could theoretically support many multiples of current revenue. In practice, the operating leverage is unrealised: FY25 group revenue was £0.66m (entirely from Everfex FX, not from the platform); there is no reported ARR, no per-deployment pricing disclosed, and no observable gross-margin ladder. If Conister converts to a recurring per-transaction licence at even modest scale, incremental gross margins could plausibly be 70%+ — but the base is so small that a 10-20% "beat" is meaningless in absolute terms. Realistically, Fiinu is a pre-inflection business where the leverage exists in the cost structure but has not been proven in revenue 2026-06 FY25 income statement; 2025-08 admission document.
Value-trap signals
- Cumulative retained losses of £26.6m against £2.9m net equity 2026-06 FY25 balance sheet.
- Full goodwill write-off of the sole acquisition within a year of completion 2026-06 FY25.
- Repeated raises at declining prices (10p → 15p → shares now trade at 4p).
- Going-concern material uncertainty noted in the FY24 audit report 2025-05 final results notes.
- Related-party transactions (Dewscope loan/conversion, Horrocks participations, Sprift secured loan) recurring across multiple periods.
- Public activist shareholder letter from the Everfex vendor ahead of the 2026 AGM.
- Board-level churn: banking licence returned, CEO/CFO/CSO/INED departures across 2023–2026.
- CEO LTIP explicitly targeting a 1,000% share price rise (110p / £440m mcap) within 36 months — indicative of aspirational rather than grounded planning 2025-09 half-year.
Earnings vs. expectations
Fiinu does not publish quantitative guidance or have covered analyst consensus; the reference points are qualitative milestones set by management. Against those, the pattern is a string of visible misses: (a) failure to raise exit capital and return of banking licence (2023); (b) Q4 2025 white-label launch guided in Jan 2025 slipped to "end of summer 2026" 2025-09 half-year vs 2026-06 FY25; (c) Everfex FY25 performance materially below the "profitable, scalable" pitch, with full goodwill impairment 12 months post-close 2025-08 admission document vs 2026-06 FY25. Only the cost-out (burn reduced from £600k/month in 2023 to £45k in 2024, then rebuilt to ~£220k in 2025) was delivered on plan. Overall trend: more misses than beats.
Conviction
2 / 5 (low). I am confident directionally that the shares are fair-to-slightly-expensive rather than deeply mispriced, but the underlying business is too unstable to defend a tight range.
- Anchors: transparent cash position, clear disclosure of the FY25 impairment and legal dispute, unambiguous evidence of prior strategic reversals.
- Limits: (a) the Plugin Overdraft has no proven per-deployment economics — the range 2p–6p reflects wide uncertainty on optionality; (b) the Everfex legal outcome is genuinely binary and unquantifiable from the filings; (c) further dilutive fundraising is likely and its price is unknowable.